24-Jul-2026
Exagen to Announce Second Quarter Financial Results on August 4, 2026
Globe Newswire (Tue, 21-Jul 9:00 AM ET)
Globe Newswire (Mon, 1-Jun 9:00 AM ET)
Exagen's Q1 2026: Record Revenue and Cash Reserves Hint at Strategic Momentum for XGN
Market Chameleon (Mon, 11-May 6:30 AM ET)
Exagen Inc. Reports First Quarter 2026 Results
Globe Newswire (Mon, 11-May 8:00 AM ET)
Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026
Globe Newswire (Mon, 27-Apr 9:00 AM ET)
XGN Delivers Record Revenue and Higher Margins in Q3 2025: Focus Shifts to Pathway for Profitability
Market Chameleon (Tue, 4-Nov 4:15 AM ET)
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.
Exagen trades on the NASDAQ stock market under the symbol XGN.
As of July 24, 2026, XGN stock price declined to $4.68 with 185,706 million shares trading.
XGN has a beta of 1.83, meaning it tends to be more sensitive to market movements. XGN has a correlation of 0.10 to the broad based SPY ETF.
XGN has a market cap of $112.99 million. This is considered a Micro Cap stock.
Last quarter Exagen reported $17 million in Revenue and -$.17 earnings per share. This beat revenue expectation by $869,144 and exceeded earnings estimates by $.08.
In the last 3 years, XGN traded as high as $12.23 and as low as $1.30.
The top ETF exchange traded funds that XGN belongs to (by Net Assets): VTI, VXF, IWC, DFAS, QQQS.
XGN has underperformed the market in the last year with a return of -35.2%, while SPY returned +17.7%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in XGN shares. However, XGN has outperformed the market in the last 3 month and 2 week periods, returning +73.3% and +5.2%, while SPY returned +3.8% and -2.1%, respectively. This indicates XGN has been having a stronger performance recently.
XGN support price is $4.70 and resistance is $5.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XGN shares will trade within this expected range on the day.